Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
saRNA COVID-19 vaccine
- Development stage
- Unknown
- Lead developer
- VLP Therapeutics Japan
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The saRNA COVID-19 vaccine is a self-amplifying RNA (saRNA) vaccine program developed by VLP Therapeutics (and its subsidiary VLP Therapeutics Japan) for the prevention of COVID-19 caused by SARS-CoV-2. The vaccine platform utilizes a self-amplifying replicon RNA delivered via lipid nanoparticles (LNPs). The initial candidate, VLPCOV-01, encodes a membrane-anchored receptor-binding domain (RBD) derived from the ancestral SARS-CoV-2 spike protein. To reduce reactogenicity, the platform was updated in VLPCOV-02 by incorporating a modified base, 5-methylcytosine (5mC), and updating the RBD to target the Gamma variant. Subsequent iterations include VLPCOV-04 (targeting Omicron XBB.1.5) and VLPCOV-05 (targeting Omicron JN.1), which have progressed to Phase 3 clinical trials in Japan as booster vaccines. The self-amplifying mechanism allows for robust and prolonged antigen expression at significantly lower doses compared to conventional mRNA vaccines.
- Other names
- replicon COVID-19 vaccinesaRNA SARS-CoV-2 vaccineself-amplifying RNA COVID-19 vaccine
02
Targets
nsP4 (Alphavirus RNA-dependent RNA polymerase)
Beyond the preview
Go deeper on saRNA COVID-19 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on saRNA COVID-19 vaccine.